103 related articles for article (PubMed ID: 32427884)
21. Evidence for control of protein synthesis in HeLa cells via the elongation rate.
Nielsen PJ; McConkey EH
J Cell Physiol; 1980 Sep; 104(3):269-81. PubMed ID: 7419605
[TBL] [Abstract][Full Text] [Related]
22. Rodent fibroblast tumours expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression.
Wyllie AH; Rose KA; Morris RG; Steel CM; Foster E; Spandidos DA
Br J Cancer; 1987 Sep; 56(3):251-9. PubMed ID: 3663473
[TBL] [Abstract][Full Text] [Related]
23. Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation.
Ryazanov AG; Shestakova EA; Natapov PG
Nature; 1988 Jul; 334(6178):170-3. PubMed ID: 3386756
[TBL] [Abstract][Full Text] [Related]
24. The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.
Griffin RL; Shuman L; Yamashita H; Wu Q; Chen G; Brown RM; Vander Griend D; DeGraff DJ; Warrick JI
Am J Clin Exp Urol; 2024; 12(2):88-99. PubMed ID: 38736621
[TBL] [Abstract][Full Text] [Related]
25. Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer.
Sanya DRA; Onésime D
Hum Cell; 2023 Jul; 36(4):1343-1372. PubMed ID: 37209205
[TBL] [Abstract][Full Text] [Related]
26. The expression of stem cells markers and its effects on the propensity for recurrence and metastasis in bladder cancer: A systematic review.
Hamid ARAH; Syadza YZ; Yausep OE; Christanto RBI; Muharia BHR; Mochtar CA
PLoS One; 2023; 18(5):e0269214. PubMed ID: 37196048
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with Bladder Cancer.
Rasti A; Khalili M; Fakhr Yasseri AM; Nasirian N; Shirkoohi R; Nowroozi MR; Modarressi MH
Rep Biochem Mol Biol; 2023 Jan; 11(4):710-719. PubMed ID: 37131897
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.
Jana S; Brahma S; Arora S; Wladyka CL; Hoang P; Blinka S; Hough R; Horn JL; Liu Y; Wang LJ; Depeille P; Smith E; Montgomery RB; Lee JK; Haffner MC; Vakar-Lopez F; Grivas P; Wright JL; Lam HM; Black PC; Roose JP; Ryazanov AG; Subramaniam AR; Henikoff S; Hsieh AC
Cancer Cell; 2023 May; 41(5):853-870.e13. PubMed ID: 37084735
[TBL] [Abstract][Full Text] [Related]
29. SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis.
Njouendou AJ; Szarvas T; Tiofack AAZ; Kenfack RN; Tonouo PD; Ananga SN; Bell EHMD; Simo G; Hoheisel JD; Siveke JT; Lueong SS
Mol Cancer; 2023 Mar; 22(1):52. PubMed ID: 36932385
[TBL] [Abstract][Full Text] [Related]
30. IGF2: A Role in Metastasis and Tumor Evasion from Immune Surveillance?
Belfiore A; Rapicavoli RV; Le Moli R; Lappano R; Morrione A; De Francesco EM; Vella V
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672737
[TBL] [Abstract][Full Text] [Related]
31. Impact of SOX2 function and regulation on therapy resistance in bladder cancer.
Chen G; Chen Y; Xu R; Zhang G; Zou X; Wu G
Front Oncol; 2022; 12():1020675. PubMed ID: 36465380
[TBL] [Abstract][Full Text] [Related]
32. Targeted Inhibition of O-Linked β-N-Acetylglucosamine Transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor Traits in Chemoresistant Urothelial Carcinoma of the Bladder.
Lee HW; Kang MJ; Kwon YJ; Abdi Nansa S; Jung EH; Kim SH; Lee SJ; Jeong KC; Kim Y; Cheong H; Seo HK
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625898
[TBL] [Abstract][Full Text] [Related]
33. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
34. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
35. Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway.
Tian B; Zhao Y; Liang T; Ye X; Li Z; Yan D; Fu Q; Li Y
J Drug Target; 2017 Aug; 25(7):626-636. PubMed ID: 28286973
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
Huang GS; Brouwer-Visser J; Ramirez MJ; Kim CH; Hebert TM; Lin J; Arias-Pulido H; Qualls CR; Prossnitz ER; Goldberg GL; Smith HO; Horwitz SB
Clin Cancer Res; 2010 Jun; 16(11):2999-3010. PubMed ID: 20404007
[TBL] [Abstract][Full Text] [Related]
37. SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer.
Schaefer T; Steiner R; Lengerke C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664542
[TBL] [Abstract][Full Text] [Related]
38. Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog).
Lee S; Wottrich S; Bonavida B
Tumour Biol; 2017 Apr; 39(4):1010428317692253. PubMed ID: 28378634
[TBL] [Abstract][Full Text] [Related]
39. Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer.
Chiu YF; Wu CC; Kuo MH; Miao CC; Zheng MY; Chen PY; Lin SC; Chang JL; Wang YH; Chou YT
Sci Rep; 2020 May; 10(1):8261. PubMed ID: 32427884
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
